{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T18:01:34Z","timestamp":1774807294765,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.urolonc.2020.05.032","type":"journal-article","created":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T03:47:48Z","timestamp":1594957668000},"page":"736.e11-736.e18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Does grossly complete transurethral resection improve response to neoadjuvant chemotherapy?"],"prefix":"10.1016","volume":"38","author":[{"given":"Rashed A.","family":"Ghandour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Kusin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaosong","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirmish","family":"Singla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuval","family":"Freifeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditya","family":"Bagrodia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vitaly","family":"Margulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Sagalowsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yair","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solomon L.","family":"Woldu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2020.05.032_bib0001","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2020.05.032_bib0002","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1002\/cncr.29047","article-title":"Bladder cancer collaborative stage variables and their data quality, usage, and clinical implications: a review of SEER data, 2004-2010.","author":"Charlton","year":"2014","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2020.05.032_bib0003","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO Guideline","volume":"198","author":"Chang","year":"2017","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2020.05.032_bib0004","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2016.06.020","article-title":"Updated 2016 EAU Guidelines on muscle-invasive and metastatic bladder cancer","volume":"71","author":"Alfred Witjes","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.05.032_bib0005","series-title":"NCCN clinical practice guidelines in oncology: bladder cancer, version 5.2018","year":"2018"},{"issue":"9","key":"10.1016\/j.urolonc.2020.05.032_bib0006","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.urolonc.2020.05.032_bib0007","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration","volume":"48","year":"2005","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2020.05.032_bib0008","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.eururo.2014.02.038","article-title":"Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review","volume":"66","author":"Ploussard","year":"2014","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2020.05.032_bib0009","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.juro.2018.05.078","article-title":"Conservative management following complete clinical response to neoadjuvant chemotherapy of muscle invasive bladder cancer: contemporary outcomes of a multi-institutional cohort study","volume":"200","author":"Mazza","year":"2018","journal-title":"J Urol"},{"issue":"7","key":"10.1016\/j.urolonc.2020.05.032_bib0010","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.trecan.2019.05.011","article-title":"Treatment options and outcomes in nonmetastatic muscle invasive bladder cancer","volume":"5","author":"Ghandour","year":"2019","journal-title":"Trends Cancer"},{"key":"10.1016\/j.urolonc.2020.05.032_bib0011","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/1756-0500-7-167","article-title":"Delayed spontaneous perforation of urinary bladder with intraperitoneal seeding following radical transurethral resection of invasive urothelial cancer: a case report","volume":"7","author":"Kim","year":"2014","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.urolonc.2020.05.032_bib0012","article-title":"Tumour seeding as a result of intraperitoneal perforation during transurethral resection of non-muscle invasive bladder cancer","volume":"2014","author":"Cusano","year":"2014","journal-title":"Case Reports"},{"issue":"5","key":"10.1016\/j.urolonc.2020.05.032_bib0013","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s00345-013-1197-x","article-title":"Perforation during TUR of bladder tumours influences the natural history of superficial bladder cancer","volume":"32","author":"Comploj","year":"2014","journal-title":"World J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2020.05.032_bib0014","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.eururo.2007.12.031","article-title":"Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"54","author":"Herr","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.05.032_bib0015","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1007\/s00345-019-02734-6","article-title":"The impact of completeness of last transurethral resection of bladder tumors on the outcomes of radical cystectomy","volume":"37","author":"Zamboni","year":"2019","journal-title":"World J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2020.05.032_bib0016","doi-asserted-by":"crossref","first-page":"287-91","DOI":"10.1016\/j.clgc.2014.01.005","article-title":"Role of maximal endoscopic resection before cystectomy for invasive urothelial bladder cancer","volume":"12","author":"James","year":"2014","journal-title":"Clin Genitourin Cancer"},{"issue":"10","key":"10.1016\/j.urolonc.2020.05.032_bib0017","first-page":"4497","article-title":"Retrospective analysis of the efficacy of two cycles of M-VAC neoadjuvant chemotherapy followed by radical cystectomy for muscle-invasive bladder cancer","volume":"33","author":"Kitagawa","year":"2013","journal-title":"Anticancer Res"},{"issue":"2","key":"10.1016\/j.urolonc.2020.05.032_bib0018","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.eururo.2010.03.007","article-title":"Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial","volume":"58","author":"Divrik","year":"2010","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.urolonc.2020.05.032_bib0019","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1002\/(SICI)1097-0142(19991201)86:11<2337::AID-CNCR23>3.0.CO;2-6","article-title":"Influence of smoking status on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma of the bladder","volume":"86","author":"Fleshner","year":"1999","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.urolonc.2020.05.032_bib0020","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/bju.14612","volume":"123","author":"Boeri","year":"2019","journal-title":"BJU Int"},{"issue":"12","key":"10.1016\/j.urolonc.2020.05.032_bib0021","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.purol.2018.07.003","article-title":"[ypT0N0 after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer: Incidence and prognosis. A review from the Bladder group of the French Committee of Oncology]","volume":"28","author":"Pignot","year":"2018","journal-title":"Prog Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2020.05.032_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2016.08.005","article-title":"Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?","volume":"35","author":"Brant","year":"2017","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2020.05.032_bib0023","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20040793","article-title":"Molecular predictors of complete response following neoadjuvant chemotherapy in urothelial carcinoma of the bladder and upper tracts","volume":"20","author":"Tse","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.urolonc.2020.05.032_bib0024","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1097\/01.ju.0000181811.61199.35","article-title":"The actual incidence of bladder perforation following transurethral bladder surgery","volume":"174","author":"Balbay","year":"2005","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2020.05.032_bib0025","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.urology.2003.12.035","article-title":"Impact of transurethral resection of bladder tumor: analysis of cystectomy specimens to evaluate for residual tumor","volume":"63","author":"Lee","year":"2004","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.urolonc.2020.05.032_bib0026","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.eururo.2017.05.016","article-title":"Oncologic outcomes for patients with residual cancer at cystectomy following neoadjuvant chemotherapy: a pathologic stage-matched analysis","volume":"72","author":"Bhindi","year":"2017","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2020.05.032_bib0027","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.eururo.2006.05.021","article-title":"Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy","volume":"51","author":"Shariat","year":"2007","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2020.05.032_bib0028","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.juro.2009.01.115","article-title":"A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219)","volume":"181","author":"deVere White","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.05.032_bib0029","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20190401","article-title":"Multiparametric MRI in differentiation between muscle invasive and non-muscle invasive urinary bladder cancer with vesical imaging reporting and data system (VI-RADS) application","author":"Makboul","year":"2019","journal-title":"Br J Radiol"},{"issue":"18","key":"10.1016\/j.urolonc.2020.05.032_bib0030","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.05.032_bib0031","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.437","volume":"38","author":"Culine","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920302635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920302635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:18:17Z","timestamp":1761041897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143920302635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1078143920302635"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.05.032","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does grossly complete transurethral resection improve response to neoadjuvant chemotherapy?","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.05.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}